<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36991279</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>The Fragile X Protein Family in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>3898</StartPage><EndPage>3910</EndPage><MedlinePgn>3898-3910</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-023-03330-x</ELocationID><Abstract><AbstractText>The fragile X protein (FXP) family comprises the multifunctional RNA-binding proteins FMR1, FXR1, and FXR2 that play an important role in RNA metabolism and regulation of translation, but also in DNA damage and cellular stress responses, mitochondrial organization, and more. FMR1 is well known for its implication in neurodevelopmental diseases. Recent evidence suggests substantial contribution of this protein family to amyotrophic lateral sclerosis (ALS) pathogenesis. ALS is a highly heterogeneous neurodegenerative disease with multiple genetic and unclear environmental causes and very limited treatment options. The loss of motoneurons in ALS is still poorly understood, especially because pathogenic mechanisms are often restricted to patients with mutations in specific causative genes. Identification of converging disease mechanisms evident in most patients and suitable for therapeutic intervention is therefore of high importance. Recently, deregulation of the FXPs has been linked to pathogenic processes in different types of ALS. Strikingly, in many cases, available data points towards loss of expression and/or function of the FXPs early in the disease, or even at the presymptomatic state. In this review, we briefly introduce the FXPs and summarize available data about these proteins in ALS. This includes their relation to TDP-43, FUS, and ALS-related miRNAs, as well as their possible contribution to pathogenic protein aggregation and defective RNA editing. Furthermore, open questions that need to be addressed before definitively judging suitability of these proteins as novel therapeutic targets are discussed.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mueller</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Albert-Einstein-Allee 11, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Decker</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Albert-Einstein-Allee 11, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Menge</LastName><ForeName>Sonja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Albert-Einstein-Allee 11, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Albert-Einstein-Allee 11, 89081, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center For Neurodegenerative Diseases (DZNE) Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freischmidt</LastName><ForeName>Axel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1216-3790</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Albert-Einstein-Allee 11, 89081, Ulm, Germany. axel.freischmidt@uni-ulm.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C096916">FXR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497683">FMR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>139135-51-6</RegistryNumber><NameOfSubstance UI="D051860">Fragile X Mental Retardation Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051860" MajorTopicYN="N">Fragile X Mental Retardation Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis&#xa0;ALS</Keyword><Keyword MajorTopicYN="N">FMR1 FMRP</Keyword><Keyword MajorTopicYN="N">FXR1 FXR1P</Keyword><Keyword MajorTopicYN="N">FXR2 FXR2P</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">Protein aggregation</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36991279</ArticleId><ArticleId IdType="pmc">PMC10224833</ArticleId><ArticleId IdType="doi">10.1007/s12035-023-03330-x</ArticleId><ArticleId IdType="pii">10.1007/s12035-023-03330-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder M, Johnson RH, Palanisamy V. Fragile X-related protein family: a double-edged sword in neurodevelopmental disorders and cancer. Crit Rev Biochem Mol Biol. 2020;55:409&#x2013;424. doi: 10.1080/10409238.2020.1810621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10409238.2020.1810621</ArticleId><ArticleId IdType="pmc">PMC7695039</ArticleId><ArticleId IdType="pubmed">32878499</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter JD, Zhao X. The molecular biology of FMRP: new Insights into Fragile X Syndrome. Nat Rev Neurosci. 2021;22:209&#x2013;222. doi: 10.1038/s41583-021-00432-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00432-0</ArticleId><ArticleId IdType="pmc">PMC8094212</ArticleId><ArticleId IdType="pubmed">33608673</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Nott TJ, Jin J, Pawson T. Deciphering arginine methylation: Tudor tells the tale. Nat Rev Mol Cell Biol. 2011;12:629&#x2013;642. doi: 10.1038/nrm3185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3185</ArticleId><ArticleId IdType="pubmed">21915143</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Goswami A, Limm K, et al. A serum microRNA sequence reveals fragile X protein pathology in amyotrophic lateral sclerosis. Brain J Neurol. 2021;144:1214&#x2013;1229. doi: 10.1093/brain/awab018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab018</ArticleId><ArticleId IdType="pmc">PMC8105042</ArticleId><ArticleId IdType="pubmed">33871026</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Koppers M, Groen EJN, et al. Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways. Acta Neuropathol (Berl) 2016;132:175&#x2013;196. doi: 10.1007/s00401-016-1575-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1575-8</ArticleId><ArticleId IdType="pmc">PMC4947123</ArticleId><ArticleId IdType="pubmed">27164932</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Ge W. The tandem Agenet domain of fragile X mental retardation protein interacts with FUS. Sci Rep. 2017;7:962. doi: 10.1038/s41598-017-01175-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-01175-8</ArticleId><ArticleId IdType="pmc">PMC5430443</ArticleId><ArticleId IdType="pubmed">28424484</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Madl T, Valori CF, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 2012;31:4258&#x2013;4275. doi: 10.1038/emboj.2012.261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.261</ArticleId><ArticleId IdType="pmc">PMC3501225</ArticleId><ArticleId IdType="pubmed">22968170</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum M, Chang H-Y, Chuguransky S, et al. The InterPro protein families and domains database: 20 years on. Nucleic Acids Res. 2021;49:D344&#x2013;D354. doi: 10.1093/nar/gkaa977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa977</ArticleId><ArticleId IdType="pmc">PMC7778928</ArticleId><ArticleId IdType="pubmed">33156333</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M, Fagerberg L, Hallstr&#xf6;m BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi: 10.1126/science.1260419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Ifrim MF, Valdez AN, et al. Aberrant RNA translation in fragile X syndrome: from FMRP mechanisms to emerging therapeutic strategies. Brain Res. 2018;1693:24&#x2013;36. doi: 10.1016/j.brainres.2018.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.04.008</ArticleId><ArticleId IdType="pmc">PMC7377270</ArticleId><ArticleId IdType="pubmed">29653083</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Chen X, Xing R, et al. Interplay between FMRP and lncRNA TUG1 regulates axonal development through mediating SnoN-Ccd1 pathway. Hum Mol Genet. 2018;27:475&#x2013;485. doi: 10.1093/hmg/ddx417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx417</ArticleId><ArticleId IdType="pubmed">29211876</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha MS, Haghighi F, Stefanski A, et al. Novel FMRP interaction networks linked to cellular stress. FEBS J. 2021;288:837&#x2013;860. doi: 10.1111/febs.15443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15443</ArticleId><ArticleId IdType="pubmed">32525608</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng P-Y, Klyachko VA. Channelopathies in fragile X syndrome. Nat Rev Neurosci. 2021;22:275&#x2013;289. doi: 10.1038/s41583-021-00445-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00445-9</ArticleId><ArticleId IdType="pmc">PMC8863066</ArticleId><ArticleId IdType="pubmed">33828309</ArticleId></ArticleIdList></Reference><Reference><Citation>Glauninger H, Wong Hickernell CJ, Bard JAM, Drummond DA. Stressful steps: progress and challenges in understanding stress-induced mRNA condensation and accumulation in stress granules. Mol Cell. 2022;82:2544&#x2013;2556. doi: 10.1016/j.molcel.2022.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2022.05.014</ArticleId><ArticleId IdType="pmc">PMC9308734</ArticleId><ArticleId IdType="pubmed">35662398</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S, Wheeler JR, Walters RW, et al. ATPase-modulated stress granules contain a diverse proteome and substructure. Cell. 2016;164:487&#x2013;498. doi: 10.1016/j.cell.2015.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.038</ArticleId><ArticleId IdType="pmc">PMC4733397</ArticleId><ArticleId IdType="pubmed">26777405</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazroui R, Huot M-E, Tremblay S, et al. Trapping of messenger RNA by fragile X mental retardation protein into cytoplasmic granules induces translation repression. Hum Mol Genet. 2002;11:3007&#x2013;3017. doi: 10.1093/hmg/11.24.3007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/11.24.3007</ArticleId><ArticleId IdType="pubmed">12417522</ArticleId></ArticleIdList></Reference><Reference><Citation>Didiot M-C, Subramanian M, Flatter E, et al. Cells lacking the fragile X mental retardation protein (FMRP) have normal RISC activity but exhibit altered stress granule assembly. Mol Biol Cell. 2009;20:428&#x2013;437. doi: 10.1091/mbc.E08-07-0737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E08-07-0737</ArticleId><ArticleId IdType="pmc">PMC2613094</ArticleId><ArticleId IdType="pubmed">19005212</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon SJ, Han S-H, Yang S-I, et al. Positive feedback regulation of Akt-FMRP pathway protects neurons from cell death. J Neurochem. 2012;123:226&#x2013;238. doi: 10.1111/j.1471-4159.2012.07886.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07886.x</ArticleId><ArticleId IdType="pubmed">22817682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon SJ, Seo JE, Yang S-I, et al. Cellular stress-induced up-regulation of FMRP promotes cell survival by modulating PI3K-Akt phosphorylation cascades. J Biomed Sci. 2011;18:17. doi: 10.1186/1423-0127-18-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-18-17</ArticleId><ArticleId IdType="pmc">PMC3045291</ArticleId><ArticleId IdType="pubmed">21314987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornbeck PV, Zhang B, Murray B, et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015;43:D512&#x2013;D520. doi: 10.1093/nar/gku1267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1267</ArticleId><ArticleId IdType="pmc">PMC4383998</ArticleId><ArticleId IdType="pubmed">25514926</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto M, Folci A, Martin S. Post-translational modifications of the fragile X mental retardation protein in neuronal function and dysfunction. Mol Psychiatry. 2020;25:1688&#x2013;1703. doi: 10.1038/s41380-019-0629-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0629-4</ArticleId><ArticleId IdType="pubmed">31822816</ArticleId></ArticleIdList></Reference><Reference><Citation>Say E, Tay H-G, Zhao Z, et al. A functional requirement for PAK1 binding to the KH(2) domain of the fragile X protein-related FXR1. Mol Cell. 2010;38:236&#x2013;249. doi: 10.1016/j.molcel.2010.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2010.04.004</ArticleId><ArticleId IdType="pubmed">20417602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman RJ, Berry-Kravis E, Hazlett HC, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065. doi: 10.1038/nrdp.2017.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.65</ArticleId><ArticleId IdType="pubmed">28960184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosario R, Anderson R. The molecular mechanisms that underlie fragile X-associated premature ovarian insufficiency: is it RNA or protein based? Mol Hum Reprod. 2020;26:727&#x2013;737. doi: 10.1093/molehr/gaaa057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molehr/gaaa057</ArticleId><ArticleId IdType="pmc">PMC7566375</ArticleId><ArticleId IdType="pubmed">32777047</ArticleId></ArticleIdList></Reference><Reference><Citation>Liufu T, Zheng Y, Yu J, et al. The polyG diseases: a new disease entity. Acta Neuropathol Commun. 2022;10:79. doi: 10.1186/s40478-022-01383-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-022-01383-y</ArticleId><ArticleId IdType="pmc">PMC9153130</ArticleId><ArticleId IdType="pubmed">35642014</ArticleId></ArticleIdList></Reference><Reference><Citation>Aishworiya R, Protic D, Hagerman R. Autism spectrum disorder in the fragile X premutation state: possible mechanisms and implications. J Neurol. 2022;269:4676&#x2013;4683. doi: 10.1007/s00415-022-11209-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11209-5</ArticleId><ArticleId IdType="pubmed">35723724</ArticleId></ArticleIdList></Reference><Reference><Citation>Esta&#xf1; MC, Fern&#xe1;ndez-N&#xfa;&#xf1;ez E, Zaki MS, et al. Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. Nat Commun. 2019;10:797. doi: 10.1038/s41467-019-08548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-08548-9</ArticleId><ArticleId IdType="pmc">PMC6377633</ArticleId><ArticleId IdType="pubmed">30770808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bampton A, Gittings LM, Fratta P, et al. The role of hnRNPs in frontotemporal dementia and amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 2020;140:599&#x2013;623. doi: 10.1007/s00401-020-02203-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02203-0</ArticleId><ArticleId IdType="pmc">PMC7547044</ArticleId><ArticleId IdType="pubmed">32748079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 2012;124:339&#x2013;352. doi: 10.1007/s00401-012-1022-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1022-4</ArticleId><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, Ishigaki S, Iguchi Y, et al. Characteristic features of FUS inclusions in spinal motor neurons of sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2020;79:370&#x2013;377. doi: 10.1093/jnen/nlaa003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlaa003</ArticleId><ArticleId IdType="pubmed">32142134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Luisier R, Taha DM, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain J Neurol. 2019;142:2572&#x2013;2580. doi: 10.1093/brain/awz217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz217</ArticleId><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan M, Talbot K, Ansorge O. Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. Acta Neuropathol Commun. 2016;4:99. doi: 10.1186/s40478-016-0358-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0358-8</ArticleId><ArticleId IdType="pmc">PMC5011941</ArticleId><ArticleId IdType="pubmed">27600654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang I-F, Wu L-S, Chang H-Y, Shen C-KJ. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem. 2008;105:797&#x2013;806. doi: 10.1111/j.1471-4159.2007.05190.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05190.x</ArticleId><ArticleId IdType="pubmed">18088371</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Fan D, Gui B, et al. Neurodegeneration-associated TDP-43 interacts with fragile X mental retardation protein (FMRP)/Staufen (STAU1) and regulates SIRT1 expression in neuronal cells. J Biol Chem. 2012;287:22560&#x2013;22572. doi: 10.1074/jbc.M112.357582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.357582</ArticleId><ArticleId IdType="pmc">PMC3391095</ArticleId><ArticleId IdType="pubmed">22584570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu J-F, Majumder P, Chatterjee B, et al. TDP-43 Regulates coupled dendritic mRNA transport-translation processes in co-operation with FMRP and Staufen1. Cell Rep. 2019;29:3118&#x2013;3133.e6. doi: 10.1016/j.celrep.2019.10.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.10.061</ArticleId><ArticleId IdType="pubmed">31801077</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder P, Chu J-F, Chatterjee B, et al. Co-regulation of mRNA translation by TDP-43 and Fragile X Syndrome protein FMRP. Acta Neuropathol (Berl) 2016;132:721&#x2013;738. doi: 10.1007/s00401-016-1603-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1603-8</ArticleId><ArticleId IdType="pmc">PMC5073124</ArticleId><ArticleId IdType="pubmed">27518042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro D, Yao S, Zarnescu DC. Dynamic duo - FMRP and TDP-43: Regulating common targets, causing different diseases. Brain Res. 2018;1693:37&#x2013;42. doi: 10.1016/j.brainres.2018.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.04.034</ArticleId><ArticleId IdType="pmc">PMC5997554</ArticleId><ArticleId IdType="pubmed">29715444</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Yamada SB, Siddegowda BB, et al. Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation. Hum Mol Genet. 2015;24:6886&#x2013;6898. doi: 10.1093/hmg/ddv389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv389</ArticleId><ArticleId IdType="pmc">PMC5007633</ArticleId><ArticleId IdType="pubmed">26385636</ArticleId></ArticleIdList></Reference><Reference><Citation>El Fatimy R, Davidovic L, Tremblay S, et al. Tracking the fragile X mental retardation protein in a highly ordered neuronal ribonucleoparticles population: a link between stalled polyribosomes and RNA granules. PLoS Genet. 2016;12:e1006192. doi: 10.1371/journal.pgen.1006192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006192</ArticleId><ArticleId IdType="pmc">PMC4963131</ArticleId><ArticleId IdType="pubmed">27462983</ArticleId></ArticleIdList></Reference><Reference><Citation>Birsa N, Ule AM, Garone MG, et al. FUS-ALS mutants alter FMRP phase separation equilibrium and impair protein translation. Sci Adv. 2021;7:eabf8660. doi: 10.1126/sciadv.abf8660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abf8660</ArticleId><ArticleId IdType="pmc">PMC8294762</ArticleId><ArticleId IdType="pubmed">34290090</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson MK, St&#xe5;hlberg A, Arvidsson Y, et al. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 2008;9:37. doi: 10.1186/1471-2121-9-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2121-9-37</ArticleId><ArticleId IdType="pmc">PMC2478660</ArticleId><ArticleId IdType="pubmed">18620564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M, Chen J, Kuang L, et al. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. Proc Natl Acad Sci U S A. 2018;115:E11904&#x2013;E11913. doi: 10.1073/pnas.1810413115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1810413115</ArticleId><ArticleId IdType="pmc">PMC6304956</ArticleId><ArticleId IdType="pubmed">30455313</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, Qamar S, Lin JQ, et al. ALS/FTD mutation-induced phase transition of FUS liquid droplets and reversible hydrogels into irreversible hydrogels impairs RNP granule function. Neuron. 2015;88:678&#x2013;690. doi: 10.1016/j.neuron.2015.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.030</ArticleId><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe9;vigny M, Bourdeau Julien I, Venkatasubramani JP, et al. FUS contributes to mTOR-dependent inhibition of translation. J Biol Chem. 2020;295:18459&#x2013;18473. doi: 10.1074/jbc.RA120.013801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.013801</ArticleId><ArticleId IdType="pmc">PMC7939483</ArticleId><ArticleId IdType="pubmed">33082139</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda K, Zhang H, Loiselle D, et al. The RNA-binding protein Fus directs translation of localized mRNAs in APC-RNP granules. J Cell Biol. 2013;203:737&#x2013;746. doi: 10.1083/jcb.201306058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201306058</ArticleId><ArticleId IdType="pmc">PMC3857475</ArticleId><ArticleId IdType="pubmed">24297750</ArticleId></ArticleIdList></Reference><Reference><Citation>Garone MG, Birsa N, Rosito M, et al. ALS-related FUS mutations alter axon growth in motoneurons and affect HuD/ELAVL4 and FMRP activity. Commun Biol. 2021;4:1025. doi: 10.1038/s42003-021-02538-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02538-8</ArticleId><ArticleId IdType="pmc">PMC8410767</ArticleId><ArticleId IdType="pubmed">34471224</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Cohen TJ. Aggregation of the nucleic acid-binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation. J Biol Chem. 2019;294:3696&#x2013;3706. doi: 10.1074/jbc.RA118.006351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.006351</ArticleId><ArticleId IdType="pmc">PMC6416430</ArticleId><ArticleId IdType="pubmed">30630951</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesner D, Tar L, Linkus B, et al. Reversible induction of TDP-43 granules in cortical neurons after traumatic injury. Exp Neurol. 2018;299:15&#x2013;25. doi: 10.1016/j.expneurol.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.09.011</ArticleId><ArticleId IdType="pubmed">28941811</ArticleId></ArticleIdList></Reference><Reference><Citation>Agote-Aran A, Schmucker S, Jerabkova K, et al. Spatial control of nucleoporin condensation by fragile X-related proteins. EMBO J. 2020;39:e104467. doi: 10.15252/embj.2020104467.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020104467</ArticleId><ArticleId IdType="pmc">PMC7560220</ArticleId><ArticleId IdType="pubmed">32706158</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C-C, Zhang Y, Umoh ME, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21:228&#x2013;239. doi: 10.1038/s41593-017-0047-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleixner AM, Verdone BM, Otte CG, et al. NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility. Nat Commun. 2022;13:3380. doi: 10.1038/s41467-022-31098-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31098-6</ArticleId><ArticleId IdType="pmc">PMC9192689</ArticleId><ArticleId IdType="pubmed">35697676</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Baskerville V, Zaepfel BL, et al. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci Transl Med. 2021;13:eabe1923. doi: 10.1126/scitranslmed.abe1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe1923</ArticleId><ArticleId IdType="pmc">PMC9022198</ArticleId><ArticleId IdType="pubmed">34321318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20&#x2013;51. doi: 10.1016/j.cell.2018.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.006</ArticleId><ArticleId IdType="pmc">PMC6091663</ArticleId><ArticleId IdType="pubmed">29570994</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, De Conti L, Stuani C, et al (2010) Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J 277:2268&#x2013;2281. 10.1111/j.1742-4658.2010.07643.x</Citation><ArticleIdList><ArticleId IdType="pubmed">20423455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A. 2012;109:3347&#x2013;3352. doi: 10.1073/pnas.1112427109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1112427109</ArticleId><ArticleId IdType="pmc">PMC3295278</ArticleId><ArticleId IdType="pubmed">22323604</ArticleId></ArticleIdList></Reference><Reference><Citation>Morlando M, Dini Modigliani S, Torrelli G, et al. FUS stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment. EMBO J. 2012;31:4502&#x2013;4510. doi: 10.1038/emboj.2012.319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.319</ArticleId><ArticleId IdType="pmc">PMC3545295</ArticleId><ArticleId IdType="pubmed">23232809</ArticleId></ArticleIdList></Reference><Reference><Citation>Guil S, C&#xe1;ceres JF. The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat Struct Mol Biol. 2007;14:591&#x2013;596. doi: 10.1038/nsmb1250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb1250</ArticleId><ArticleId IdType="pubmed">17558416</ArticleId></ArticleIdList></Reference><Reference><Citation>Treiber T, Treiber N, Plessmann U, et al. A compendium of RNA-binding proteins that regulate MicroRNA biogenesis. Mol Cell. 2017;66:270&#x2013;284.e13. doi: 10.1016/j.molcel.2017.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.03.014</ArticleId><ArticleId IdType="pubmed">28431233</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A, Eitan C, Liou L-L, et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J. 2015;34:2633&#x2013;2651. doi: 10.15252/embj.201490493.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201490493</ArticleId><ArticleId IdType="pmc">PMC4641530</ArticleId><ArticleId IdType="pubmed">26330466</ArticleId></ArticleIdList></Reference><Reference><Citation>Haramati S, Chapnik E, Sztainberg Y, et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A. 2010;107:13111&#x2013;13116. doi: 10.1073/pnas.1006151107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006151107</ArticleId><ArticleId IdType="pmc">PMC2919953</ArticleId><ArticleId IdType="pubmed">20616011</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, M&#xfc;ller K, Zondler L, et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain J Neurol. 2014;137:2938&#x2013;2950. doi: 10.1093/brain/awu249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu249</ArticleId><ArticleId IdType="pubmed">25193138</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, M&#xfc;ller K, Zondler L, et al. Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:2660.e15&#x2013;2660.e20. doi: 10.1016/j.neurobiolaging.2015.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.06.003</ArticleId><ArticleId IdType="pubmed">26142125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer B, K&#xf6;hler M, Sprengel R, Seeburg PH. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell. 1991;67:11&#x2013;19. doi: 10.1016/0092-8674(91)90568-j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(91)90568-j</ArticleId><ArticleId IdType="pubmed">1717158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801. doi: 10.1038/427801a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/427801a</ArticleId><ArticleId IdType="pubmed">14985749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosaka T, Tsuji H, Kwak S. RNA editing: a new therapeutic target in amyotrophic lateral sclerosis and other neurological diseases. Int J Mol Sci. 2021;22:10958. doi: 10.3390/ijms222010958.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222010958</ArticleId><ArticleId IdType="pmc">PMC8536083</ArticleId><ArticleId IdType="pubmed">34681616</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S, Alsop E, Lorenzini I, et al. ADAR2 Mislocalization and widespread RNA editing aberrations in C9orf72-Mediated ALS/FTD. Acta Neuropathol (Berl) 2019;138:49&#x2013;65. doi: 10.1007/s00401-019-01999-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01999-w</ArticleId><ArticleId IdType="pmc">PMC6750285</ArticleId><ArticleId IdType="pubmed">30945056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhogal B, Jepson JE, Savva YA, et al. Modulation of dADAR-dependent RNA editing by the Drosophila fragile X mental retardation protein. Nat Neurosci. 2011;14:1517&#x2013;1524. doi: 10.1038/nn.2950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2950</ArticleId><ArticleId IdType="pmc">PMC3225737</ArticleId><ArticleId IdType="pubmed">22037499</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamay-Ramot A, Khermesh K, Porath HT, et al (2015) Fmrp interacts with adar and regulates RNA editing, synaptic density and locomotor activity in zebrafish. PLoS Genet 11:e1005702. 10.1371/journal.pgen.1005702</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670233</ArticleId><ArticleId IdType="pubmed">26637167</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini A, Bonini D, Lacoux C, et al. Absence of the Fragile X Mental Retardation Protein results in defects of RNA editing of neuronal mRNAs in mouse. RNA Biol. 2017;14:1580&#x2013;1591. doi: 10.1080/15476286.2017.1338232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2017.1338232</ArticleId><ArticleId IdType="pmc">PMC5785225</ArticleId><ArticleId IdType="pubmed">28640668</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran SS, Jun H-I, Bahn JH, et al. Widespread RNA editing dysregulation in brains from autistic individuals. Nat Neurosci. 2019;22:25&#x2013;36. doi: 10.1038/s41593-018-0287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0287-x</ArticleId><ArticleId IdType="pmc">PMC6375307</ArticleId><ArticleId IdType="pubmed">30559470</ArticleId></ArticleIdList></Reference><Reference><Citation>La Via L, Bonini D, Russo I, et al. Modulation of dendritic AMPA receptor mRNA trafficking by RNA splicing and editing. Nucleic Acids Res. 2013;41:617&#x2013;631. doi: 10.1093/nar/gks1223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1223</ArticleId><ArticleId IdType="pmc">PMC3592400</ArticleId><ArticleId IdType="pubmed">23166306</ArticleId></ArticleIdList></Reference><Reference><Citation>Salpietro V, Dixon CL, Guo H, et al. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat Commun. 2019;10:3094. doi: 10.1038/s41467-019-10910-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10910-w</ArticleId><ArticleId IdType="pmc">PMC6626132</ArticleId><ArticleId IdType="pubmed">31300657</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim H-J, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffita-Mesa JM, Paucar M, Svenningsson P. Ataxin-2 gene: a powerful modulator of neurological disorders. Curr Opin Neurol. 2021;34:578&#x2013;588. doi: 10.1097/WCO.0000000000000959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000959</ArticleId><ArticleId IdType="pmc">PMC8279897</ArticleId><ArticleId IdType="pubmed">34010218</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Wang L, Berman M, et al. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity. 2011;35:426&#x2013;440. doi: 10.1016/j.immuni.2011.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.06.014</ArticleId><ArticleId IdType="pmc">PMC3253658</ArticleId><ArticleId IdType="pubmed">21903422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechara EG, Didiot MC, Melko M, et al. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol. 2009;7:e16. doi: 10.1371/journal.pbio.1000016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000016</ArticleId><ArticleId IdType="pmc">PMC2628407</ArticleId><ArticleId IdType="pubmed">19166269</ArticleId></ArticleIdList></Reference><Reference><Citation>Casa&#xf1;as JJ, Montesinos ML (2022) Proteomic characterization of spinal cord synaptoneurosomes from Tg-SOD1/G93A mice supports a role for MNK1 and local translation in the early stages of amyotrophic lateral sclerosis. Mol Cell Neurosci 103792. 10.1016/j.mcn.2022.103792</Citation><ArticleIdList><ArticleId IdType="pubmed">36372157</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, Gascon E, Tran H, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol (Berl) 2013;126:385&#x2013;399. doi: 10.1007/s00401-013-1149-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1149-y</ArticleId><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang P-W, Pham JT, et al. RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200. doi: 10.1038/nature13124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13124</ArticleId><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S, Serrano A, Gerbino V, et al. Nuclear accumulation of mRNAs underlies G4C2-repeat-induced translational repression in a cellular model of C9orf72 ALS. J Cell Sci. 2015;128:1787&#x2013;1799. doi: 10.1242/jcs.165332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.165332</ArticleId><ArticleId IdType="pubmed">25788698</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguete AS, Almeida S, Gao F-B, et al (2015) GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. eLife 4:e08881. 10.7554/eLife.08881</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758954</ArticleId><ArticleId IdType="pubmed">26650351</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Hitz BC, Gabdank I, et al. New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. Nucleic Acids Res. 2020;48:D882&#x2013;D889. doi: 10.1093/nar/gkz1062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1062</ArticleId><ArticleId IdType="pmc">PMC7061942</ArticleId><ArticleId IdType="pubmed">31713622</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand EL, Pratt GA, Shishkin AA, et al. Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP) Nat Methods. 2016;13:508&#x2013;514. doi: 10.1038/nmeth.3810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3810</ArticleId><ArticleId IdType="pmc">PMC4887338</ArticleId><ArticleId IdType="pubmed">27018577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Furumichi M, Sato Y et al (2022) KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res gkac963. 10.1093/nar/gkac963</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9825424</ArticleId><ArticleId IdType="pubmed">36300620</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012;33:1345&#x2013;1351. doi: 10.1002/humu.22157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22157</ArticleId><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM, Abel O, Bertram L, Al-Chalabi A. Keeping up with genetic discoveries in amyotrophic lateral sclerosis: The ALSoD and ALSGene databases. Amyotroph Lateral Scler. 2011;12:238&#x2013;249. doi: 10.3109/17482968.2011.584629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.584629</ArticleId><ArticleId IdType="pubmed">21702733</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Bailey A, Kuleshov MV, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021;1:e90. doi: 10.1002/cpz1.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpz1.90</ArticleId><ArticleId IdType="pmc">PMC8152575</ArticleId><ArticleId IdType="pubmed">33780170</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleuz&#xe9; L, Triaca V, Borreca A (2021) FMRP-Driven neuropathology in autistic spectrum disorder and alzheimer&#x2019;s disease: a losing game. Front Mol Biosci 8:699613.&#xa0;10.3389/fmolb.2021.699613</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8573832</ArticleId><ArticleId IdType="pubmed">34760921</ArticleId></ArticleIdList></Reference><Reference><Citation>Borreca A, Gironi K, Amadoro G, Ammassari-Teule M. Opposite Dysregulation of Fragile-X Mental Retardation Protein and Heteronuclear Ribonucleoprotein C Protein Associates with Enhanced APP Translation in Alzheimer Disease. Mol Neurobiol. 2016;53:3227&#x2013;3234. doi: 10.1007/s12035-015-9229-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9229-8</ArticleId><ArticleId IdType="pubmed">26048669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y, Sgobio C, Arzberger T, et al. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson&#x2019;s disease. Acta Neuropathol (Berl) 2020;139:319&#x2013;345. doi: 10.1007/s00401-019-02099-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02099-5</ArticleId><ArticleId IdType="pubmed">31768670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruf WP, Freischmidt A, Grozdanov V, et al. Protein Binding Partners of Dysregulated miRNAs in Parkinson&#x2019;s Disease Serum. Cells. 2021;10:791. doi: 10.3390/cells10040791.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040791</ArticleId><ArticleId IdType="pmc">PMC8065836</ArticleId><ArticleId IdType="pubmed">33918274</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53:1636&#x2013;1648. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113. doi: 10.1016/S1474-4422(14)70219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, D&#x2019;Alfonso S, et al. The multistep hypothesis of ALS revisited: The role of genetic mutations. Neurology. 2018;91:e635&#x2013;e642. doi: 10.1212/WNL.0000000000005996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>